BNP Paribas Financial Markets’s Nurix Therapeutics NRIX Stock Holding History

BNP Paribas Financial Markets’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.26M	Buy	340,578 +117,215	+52%	+$2M	﹤0.01%	1759
2026 Q1	$3.46M	Buy	223,363 +91,269	+69%	+$1.51M	﹤0.01%	2303
2025 Q4	$2.51M	Buy	132,094 +57,599	+77%	+$827K	﹤0.01%	2479
2025 Q3	$688K	Buy	74,495 +15,754	+27%	+$164K	﹤0.01%	3388
2025 Q2	$669K	Sell	58,741 -24,945	-30%	-$270K	﹤0.01%	3141
2025 Q1	$994K	Buy	83,686 +74,986	+862%	+$1.25M	﹤0.01%	2790
2024 Q4	$164K	Buy	+8,700	New	+$199K	﹤0.01%	3968
2022 Q4	–	Sell	-76,415	Closed	-$996K	–	4415
2022 Q3	$996K	Buy	+76,415	New	+$1.21M	﹤0.01%	2490

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

BNP Paribas Financial Markets's NRIX Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Nurix Therapeutics (NRIX) stake by 52% in Q2 2026, buying an estimated $2M and bringing the position to 340,578 shares worth $8.26M. The position accounts for ﹤0.01% of the portfolio, ranked #1759.

BNP Paribas Financial Markets first reported a position in NRIX in Q3 2022 and has held it in 8 quarters since. 194 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

BNP Paribas Financial Markets held 340,578 shares of Nurix Therapeutics worth $8.26M as of Q2 2026.
BNP Paribas Financial Markets bought 117,215 Nurix Therapeutics shares in Q2 2026, an estimated $2M.
Nurix Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #1759 holding.
BNP Paribas Financial Markets first reported a position in Nurix Therapeutics in Q3 2022 and has held it in 8 quarters since.
194 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.